Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters

被引：84
作者：
Brauch, Hiltrud [1 ,2 ]
Schroth, Werner [1 ,2 ]
Goetz, Matthew P. [3 ]
Muerdter, Thomas E. [1 ,2 ]
Winter, Stefan [1 ,2 ]
Ingle, James N. [3 ]
Schwab, Matthias [1 ,2 ,4 ]
Eichelbaum, Michel [1 ,2 ]
机构：
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
[2] Univ Tubingen, Tubingen, Germany
[3] Mayo Clin, Rochester, MN USA
[4] Univ Tubingen Hosp, Inst Expt & Clin Pharmacol & Toxicol, Tubingen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 02期
关键词：
GROUP; 1-98; TRIAL; METABOLITE PLASMA-CONCENTRATIONS; REUPTAKE INHIBITOR PAROXETINE; ESTROGEN-RECEPTOR; ACTIVE METABOLITE; RE CYP2D6; ADJUVANT TAMOXIFEN; UGT2B7; GENOTYPE; WOMEN; POLYMORPHISMS;
D O I：
10.1200/JCO.2012.44.6625
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：176 / 180
页数：5
相关论文
共 36 条
  • [1] CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen
    Abraham, Jean E.
    Maranian, Mel J.
    Driver, Kristy E.
    Platte, Radka
    Kalmyrzaev, Bolot
    Baynes, Caroline
    Luccarini, Craig
    Shah, Mitul
    Ingle, Susan
    Greenberg, David
    Earl, Helena M.
    Dunning, Alison M.
    Pharoah, Paul D. P.
    Caldas, Carlos
    [J]. BREAST CANCER RESEARCH, 2010, 12 (04)
  • [2] Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score
    Barginear, M. F.
    Jaremko, M.
    Peter, I.
    Yu, C.
    Kasai, Y.
    Kemeny, M.
    Raptis, G.
    Desnick, R. J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (04) : 605 - 611
  • [3] Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment
    Borges, Silvana
    Desta, Zeruesenay
    Li, Lang
    Skaar, Todd C.
    Ward, Bryan A.
    Nguyen, Anne
    Jin, Yan
    Storniolo, Anna Maria
    Nikoloff, D. Michele
    Wu, Lin
    Hillman, Grant
    Hayes, Daniel F.
    Stearns, Vered
    Flockhart, David A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (01) : 61 - 74
  • [4] Pharmacogenomics of Tamoxifen Therapy
    Brauch, Hiltrud
    Muerdter, Thomas E.
    Eichelbaum, Michel
    Schwab, Matthias
    [J]. CLINICAL CHEMISTRY, 2009, 55 (10) : 1770 - 1782
  • [5] Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The 'personalised' approach?
    Brauch, Hiltrud
    Jordan, V. Craig
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (13) : 2274 - 2283
  • [6] Castells A, 2000, CANCER RES, V60, P2836
  • [7] A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers
    Decensi, A
    Robertson, C
    Viale, G
    Pigatto, F
    Johansson, H
    Kisanga, ER
    Veronesi, P
    Torrisi, R
    Cazzaniga, M
    Mora, S
    Sandri, MT
    Pelosi, G
    Luini, A
    Goldhirsch, A
    Lien, EA
    Veronesi, U
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (11) : 779 - 790
  • [8] Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen
    Dowsett, M
    Haynes, BP
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2003, 86 (3-5) : 255 - 263
  • [9] Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
    Goetz, MP
    Rae, JM
    Suman, VJ
    Safgren, SL
    Ames, MM
    Visscher, DW
    Reynolds, C
    Couch, FJ
    Lingle, WL
    Flockhart, DA
    Desta, Z
    Perez, EA
    Ingle, JN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) : 9312 - 9318
  • [10] Allelic losses as prognostic markers for breast cancers
    Hirano A.
    Utada Y.
    Haga S.
    Kajiwara T.
    Sakamoto G.
    Kasumi F.
    Nakamura Y.
    Emi M.
    [J]. International Journal of Clinical Oncology, 2001, 6 (1) : 6 - 12
1234